Kiniksa Pharmaceuticals International, plc
KNSA
$19.31
$0.663.54%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 423.24M | 384.10M | 338.93M | 301.77M | 270.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 423.24M | 384.10M | 338.93M | 301.77M | 270.26M |
| Cost of Revenue | 189.22M | 149.66M | 126.64M | 105.99M | 89.93M |
| Gross Profit | 234.02M | 234.44M | 212.29M | 195.78M | 180.33M |
| SG&A Expenses | 168.01M | 164.22M | 152.28M | 139.06M | 129.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 468.86M | 410.33M | 366.44M | 332.31M | 295.46M |
| Operating Income | -45.62M | -26.24M | -27.51M | -30.54M | -25.20M |
| Income Before Tax | -36.15M | -16.72M | -18.02M | -21.56M | -16.65M |
| Income Tax Expenses | 7.04M | -7.66M | -7.79M | -30.21M | -30.74M |
| Earnings from Continuing Operations | -43.19 | -9.07 | -10.23 | 8.65 | 14.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.19M | -9.07M | -10.23M | 8.65M | 14.08M |
| EBIT | -45.62M | -26.24M | -27.51M | -30.54M | -25.20M |
| EBITDA | -43.92M | -24.40M | -25.47M | -28.33M | -22.86M |
| EPS Basic | -0.61 | -0.12 | -0.14 | 0.12 | 0.20 |
| Normalized Basic EPS | -0.32 | -0.15 | -0.16 | -0.19 | -0.15 |
| EPS Diluted | -0.61 | -0.14 | -0.16 | 0.11 | 0.19 |
| Normalized Diluted EPS | -0.32 | -0.15 | -0.16 | -0.19 | -0.15 |
| Average Basic Shares Outstanding | 285.68M | 283.74M | 282.20M | 281.11M | 280.23M |
| Average Diluted Shares Outstanding | 285.68M | 286.02M | 284.48M | 285.11M | 284.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
